ClinicalTrials.gg
TerminatedNCT04918147Updated Feb 5, 2026Results posted

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

A Phase 2 interventional study of elotuzumab and placebo for elotuzumab in IgG4 Related Disease and IgG4-RD, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Terminated at 3 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 3 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.

Enrollment
10th of 12
8 · median 18
Started
2021
the only one that year
Phase 2
7 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 9th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

3 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Immunoglobulin G4-Related Disease with a site in United States, or all of them as a file.
02

Study summary

This is a two-part multi-center clinical trial in participants with active IgG4-RD.

Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.

Part 2 (Cohort 2) is a randomized, placebo-controlled, double-blinded (masked) trial phase to compare the effects of elotuzumab and prednisone to elotuzumab placebo and prednisone in participants with IgG4 RD.

Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2. Randomization in Part 2: 2 to 1, with approximately forty-two participants randomized to elotuzumab plus prednisone taper, and twenty-one participants randomized to placebo for elotuzumab plus prednisone taper.

The total duration of participation for each participant in this trial will be 48 weeks (11 months).

Read the detailed description

Immunoglobulin G4-Related Disease (IgG4-RD) is a chronic fibro-inflammatory condition that can affect virtually every organ system, including the pancreas, biliary tract, salivary and lacrimal glands, orbits, lungs, kidneys, meninges, pituitary gland, prostate and thyroid. It may also involve the retroperitoneum. This multi-organ immune-mediated condition, once regarded as a group of isolated, single-organ diseases, is now recognized to be an overarching, single-disease entity linked by common histopathological and immunohistochemical features.

IgG4-RD tends to afflict middle-aged to elderly individuals. Although IgG4-RD can affect a single organ at presentation, it is not uncommon for participants to present with or develop multi-organ disease. As the disease progresses, additional organs develop lesions and the cellular inflammation characterizing early disease moves toward a more fibrotic stage, causing major tissue damage, dysfunction and ultimately organ failure. It is unclear whether IgG4 itself is involved in the pathogenesis of the disease.

The goals of IgG4-RD treatment are to reduce inflammation and organ swelling and to prevent or reverse tissue fibrosis. No approved therapy exists for IgG4-RD.

This study will enroll adult participants who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for IgG4-RD, and who have active IgG4-RD with disease manifestations in at least two organ systems.

Primary study objectives:

  • To determine the safety and tolerability of the addition of elotuzumab to prednisone in participants with IgG4-RD, and
  • To compare the effect of the addition of elotuzumab versus placebo to prednisone on the IgG4-RD Responder Index (IgG4-RD RI), a measure of IgG4-RD disease activity.
03

Conditions studied

  • IgG4 Related Disease
  • IgG4-RD

Keywords

  • immune-mediated fibroinflammatory disease
  • prospective trial
  • safety and efficacy
  • IgG4-RD Responder Index (IgG4-RD RI)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals who meet all of the following criteria are eligible for enrollment as study participants:

  1. Participant must be able to understand and provide and be willing to comply with study procedures and follow up.
  2. Are at least 18 years of age and not older than 70 years of age at screening.
  3. Meet the ACR/EULAR Classification Criteria for IgG4-RD [30, 31].
  4. Have active disease based at screening on an IgG4-RD RI ≥4, with disease manifestations in at least two organ systems.
  5. May have newly-diagnosed or relapsing disease at screening. Relapsing disease is defined as IgG4-RD that has previously been in remission but is now active again.
  6. May be on treatment or off treatment for IgG4-RD at the time of screening. If on treatment, must be willing to discontinue those other treatments before the baseline visit.
  7. No history of severe allergic reactions to monoclonal antibodies.
  8. Female participants of must have a negative pregnancy test upon study entry.
  9. Female participants of childbearing potential and male participants with a partner of childbearing potential must agree to consistently and correctly use FDA approved highly effective methods of for the entire duration of the study and 6 months after last elotuzumab infusion.
  10. Immunization with one of the FDA authorized or licensed SARS-CoV-2 vaccines as per CDC recommendations at the time of informed consent is required for study entry. Vaccinations must have been completed at least 2 weeks prior to start of study therapy.

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study participants:

  1. Presence of a condition other than IgG4-RD that (e.g., asthma) is likely to require systemic (GC) for disease control during the period of the trial.
  2. within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin.)
  3. The following lab values as indicators of hepatic dysfunction:

    1. Serum (AST) or alanine aminotransferase (ALT) greater than three times the (ULN)
    2. Total > two times the ULN unless caused by Gilbert's disease. Gilbert's disease with total bilirubin > three times ULN.
    3. Serum albumin \< 2.5 gm/dL.
  4. Evidence of another uncontrolled condition which, in the judgment of the investigator, could interfere with participation in the trial according to the protocol.
  5. Active infection requiring hospitalization or treatment with systemic antimicrobial agents within the 30 days prior to treatment allocation/randomization.
  6. Prior use of rituximab or other B cell depleting agents within 9 months of enrollment unless B cells have been demonstrated to have repopulated.
  7. Use of any agent or biologic and non-biologic DMARDs within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment.
  8. Any of the following laboratory tests at the Screening Visit:

    1. White blood cell count (WBC) \< 3.0 x 103/µL.
    2. (ANC) \< 1.5 x 103/µL.
    3. \< 10 g/dL.
    4. count \< 75 x 109/L.
    5. Estimated (eGFR) ≤ 45 ml/minute/1.73 m2.
  9. The use of supplemental oxygen at baseline.
  10. At or within 90 days of screening: Positive Interferon-Gamma Release Assay (IGRA). Indeterminate IGRAs must be repeated (with same or other IGRA per local policy) and shown to be negative. Alternatively, if the assay remains indeterminant, a participant must have a negative PPD. Finally, if the participant has had the Bacille Calmette-Guerin (BCG) vaccine or has some other condition complicating the interpretation of TB testing, consultation with infectious disease specialist must be obtained before receipt of the first investigational infusion.

    a. Participants diagnosed with latent TB are eligible but must have received appropriate prophylaxis for 30 days before their first investigational infusion.

  11. Medical history or serologic evidence at Screening of chronic infections including:

    1. infection.
    2. as indicated by surface antigen or hepatitis B core antibody positivity
    3. as indicated by anti-hepatitis C antibody positivity; if a participant is Hepatitis C antibody positive, they will be eligible to participate in the study if he/she is negative for viral load at Screening.
  12. within 8 weeks of initiating study therapy.
  13. Participant is pregnant or breastfeeding, or planning a pregnancy while enrolled in the study.
  14. Substance use disorder, including the recurrent use of alcohol and/or drugs within the past year associated with impairment associated with failure to meet major responsibilities at work, school, or home.
  15. IgG4-RD that is dominated primarily by advanced fibrotic lesions. Specifically, participants whose disease manifestations consist only of

    1. retroperitoneal fibrosis,
    2. fibrosing mediatinitis,
    3. sclerosing mesenteritis, or
    4. Riedel's thyroiditis. Participants with these disease manifestations can be included, however, only if they have disease in 2 organ systems that is not of an advanced fibrotic nature and otherwise meet the Inclusion and Exclusion Criteria.
  16. Evidence a SARS-CoV-2 (COVID-19) infection started within the 30 days prior to treatment allocation/randomization. Participants diagnosed with SARS-CoV-2 (COVID-19) infection more than 30 days prior to treatment allocation/randomization must have symptoms resolved and be deemed fit to participate in the trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1a: Elotuzumab-One-Month Regimen (Open-Label) + Pred Taper

    Per protocol: Six participants will receive elotuzumab on days 0,7, 14, 21, and the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered once weekly, intravenously for 4 doses, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).

    Drug: elotuzumab · Drug: methylprednisolone · Drug: diphenhydramine · Drug: acetaminophen · Drug: famotidine · Drug: prednisone

  • Experimental
    Cohort 1b: Elotuzumab-Twelve-Month Regimen (Open-Label) + Pred Taper

    Per protocol: Six participants will receive elotuzumab over a 48 week period, dose of 10mg/kg IV x 1, at baseline, then at weeks 8, 16, 24, 32 and 40 (for a total of 6 doses), with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 (baseline) that is taken orally (by mouth) daily, per protocol. Dosage in milligrams (mgs).

    Drug: elotuzumab · Drug: methylprednisolone · Drug: diphenhydramine · Drug: acetaminophen · Drug: famotidine · Drug: prednisone

  • Experimental
    Cohort 2: Arm A- Elotuzumab (Randomized) + Pred Taper

    Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Assuming no safety signal for Cohort 1, forty-two participants will receive elotuzumab per the regimen prescribed above in Part 1B, with the prescribed 10-week prednisone taper. * Elotuzumab: 10 mg/kg administered as referenced above, intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 that is taken daily by mouth, per protocol. Dosage in milligrams (mgs).

    Drug: elotuzumab · Drug: methylprednisolone · Drug: diphenhydramine · Drug: acetaminophen · Drug: famotidine · Drug: prednisone

  • Placebo comparator
    Cohort 2: Arm B-Placebo (Randomized) + Pred Taper

    Safety and efficacy analyses from Cohort 1a and Cohort 1b will occur prior to initiating Cohort 2 (Randomized). Twenty-one participants will receive placebo for elotuzumab on day 0, then weeks 8, 16, 24, 32 and 40, and the prescribed 10-week prednisone taper. * Placebo for elotuzumab: Administered on same schedule as elotuzumab described in Cohort 2 Arm A: intravenously, per protocol. * Prednisone taper (Pred Taper): Prescribed 10-week dosing taper beginning on Day 0 taken daily by mouth, per protocol. Dosage in milligrams (mgs).

    Drug: placebo for elotuzumab · Drug: methylprednisolone · Drug: diphenhydramine · Drug: acetaminophen · Drug: famotidine · Drug: prednisone

Interventions

  • Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.

    Also known as: BMS-901608, Empliciti®

  • Drugplacebo for elotuzumab

    The placebo for elotuzumab is 0.9% sterile normal saline for injection.

    Also known as: normal saline

  • Premedication administered intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).

    Also known as: Solu-Medrol®

  • Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).

    Also known as: Benadryl®

  • Premedication administered orally, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).

    Also known as: Tylenol®

  • Premedication administered orally or intravenously, 45 to 90 minutes prior to each elotuzumab/placebo infusion, per protocol. Dosage in milligrams (mg).

    Also known as: H2 blocker

  • Prescribed dosing with prednisone begins on the day of the first elotuzumab/placebo infusion, administered orally. The ten-week dosing taper proceeds, per protocol. Dosage in milligrams (mg).

    Also known as: corticosteroid

06

What researchers measure

Primary outcomes

  1. The Percent of Participants in Each Cohort Who Experience at Least One Grade 3 or Higher Adverse Event (AE).

    The severity of AEs were classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0

    Time frame: Up to Week 48 post treatment initiation

Secondary outcomes

  1. The Percent of Participants Who Experience at Least One Grade 2 or Higher Adverse Event (AE).

    The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: Up to Week 48 post treatment initiation

  2. The Percent of Participants With a Grade 3 or Higher Infection

    The number of AEs classified as infections that were Grade 3 or higher. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: Up to Week 48 post treatment initiation

  3. The Percent of Participants Who Experience a Malignancy.

    The number of participants with malignancies reported as AEs. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: Up to Week 48 post treatment initiation

  4. The Percent of Participants Who Experience a Hepatotoxicity

    Hepatotoxicity is defined as an increase in the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) to elevations three times the upper limit of normal.

    Time frame: Up to Week 48 post treatment initiation

  5. The Percent of Participants Who Experience a Serious Adverse Event

    An adverse event (AE) is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes (21 CFR 312.32(a)): 1\. Death. 2. Life-threatening event: An AE is considered "life-threatening" if, in the view of either the investigator or Sponsor, its occurrence places the participant at immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death. 3. Inpatient hospitalization or prolongation of existing hospitalization. 4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. 5. Congenital anomaly or birth defect. 6. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: Up to Week 48 post treatment initiation

  6. The Percent of Participants Who Experience Infusion Reactions

    The number of participants with infusion reactions reported as AEs. Infusion reactions are defined as any adverse reaction within 24 hours of infusion which are Grade 2 or higher events and at least possibly related to study drug. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

    Time frame: Up to 24 hours post treatment infusion

  7. The Percent of Participants That Reach the Following Threshold Levels of IgG4-Related Disease Responder Index (IgG4-RD RI) Improvement at 24 Weeks: 50% and 75%.

    The IgG4-RD RI detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). Higher scores represent greater (i.e. worse) disease activity. % improvement in the IgG4-RD RI = 100 x ( (Baseline IgG4-RD RI Activity Score - Week 24 IgG4-RD RI Activity Score) / Baseline IgG4-RD RI Activity Score). Participants who use glucocorticoids/immunosuppressants beyond that permitted by protocol, or who experience a disease flare before 24 weeks will be defined as achieving no disease response (0%).

    Time frame: Baseline and Week 24

  8. Number of Participants With Disease Flares

    IgG4-Related Disease flare was defined as recurrence of disease activity such that additional immunosuppressive therapy beyond the trial protocol is indicated. Such additional therapy may include glucocorticoids or alternative immunosuppressive agents. At the time of a potential disease flare, investigators documented the features of the disease flare in each involved organ, including laboratory evaluations, radiology studies, and other procedures (e.g., biopsy). Disease flares were reported as adverse events.

    Time frame: Up to Week 48 post treatment initiation

  9. Change From Baseline in Physician Global Assessment

    The Physician Global Assessment of the participant's current disease activity was recorded on a 100 mm linear horizontal visual analog scale, where the left hand extreme of the line is considered "Very Good" (0 mm, symptom free and no IgG4-RD symptoms) and the right hand extreme is considered "Very Bad" (100 mm, maximum IgG4-RD activity). Only active disease (as opposed to damage) is considered in the scoring. Change was calculated as the value at Week 12, 24 or 48 minus the value at Baseline.

    Time frame: Baseline, Weeks 12, 24 and 48

  10. Change From Baseline in Patient Global Assessment

    The Patient Global Assessment of the participant's current disease activity was recorded on a 100 mm linear horizontal visual analog scale, where the left hand extreme of the line is considered "Very Good" (0 mm, symptom free and no IgG4-RD symptoms) and the right hand extreme is considered "Very Bad" (100 mm, maximum IgG4-RD activity). Change was calculated as the value at Week 12, 24 or 48 minus the value at Baseline.

    Time frame: Baseline, Weeks 12, 24 and 48

  11. Disease-Related Damage, as Measured by the Damage Section of the IgG4-Related Disease (IgG4-RD) Responder Index.

    An assessment of damage caused by IgG4-RD in each affected organ is part of the Responder Index. The IgG4-RD RI encompasses more than 25 organs/sites and records the following set of information for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. Activity and damage are considered separately from the standpoint of scoring, because only disease activity can be expected to respond to treatment. Damage is defined as organ dysfunction that has occurred as a result of IgG4-RD and is considered permanent. The total damage score at each visit is defined as the total number of damaged organs and can range from 0 (no damage) to more than 26 (severe damage).

    Time frame: Screening and Week 24

07

Results

Posted Feb 25, 2025
Limitations and caveats
Failure to achieve remission along with risk of organ damage with disease flare observed in the Cohort 1b participants led to the conservative decision to stop the trial. Last Cohort 1b visit completed was Week 16; no participants enrolled in Part 2.

Participant flow

Three study sites were activated in the United States, beginning in October 2021. A total of nine participants were screened from October 2021 to October 2023 at two sites. Six participants were enrolled in Cohort 1a. Two participants were enrolled in Cohort 1b; enrollment in Cohort 1b was terminated early No participants were enrolled in Part 2.

Participant flow — Overall Study
MilestoneCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Started62
Completed60
Not completed02
Withdrew: Disease flare as defined in protocol02

Outcome measures

PrimaryThe Percent of Participants in Each Cohort Who Experience at Least One Grade 3 or Higher Adverse Event (AE).

The severity of AEs were classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants in Each Cohort Who Experience at Least One Grade 3 or Higher Adverse Event (AE).
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants in Each Cohort Who Experience at Least One Grade 3 or Higher Adverse Event (AE).51
SecondaryThe Percent of Participants Who Experience at Least One Grade 2 or Higher Adverse Event (AE).

The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants Who Experience at Least One Grade 2 or Higher Adverse Event (AE).
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants Who Experience at Least One Grade 2 or Higher Adverse Event (AE).62
SecondaryThe Percent of Participants With a Grade 3 or Higher Infection

The number of AEs classified as infections that were Grade 3 or higher. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants With a Grade 3 or Higher Infection
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants With a Grade 3 or Higher Infection30
SecondaryThe Percent of Participants Who Experience a Malignancy.

The number of participants with malignancies reported as AEs. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants Who Experience a Malignancy.
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants Who Experience a Malignancy.00
SecondaryThe Percent of Participants Who Experience a Hepatotoxicity

Hepatotoxicity is defined as an increase in the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) to elevations three times the upper limit of normal.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants Who Experience a Hepatotoxicity
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants Who Experience a Hepatotoxicity00
SecondaryThe Percent of Participants Who Experience a Serious Adverse Event

An adverse event (AE) is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes (21 CFR 312.32(a)): 1\. Death. 2. Life-threatening event: An AE is considered "life-threatening" if, in the view of either the investigator or Sponsor, its occurrence places the participant at immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death. 3. Inpatient hospitalization or prolongation of existing hospitalization. 4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions. 5. Congenital anomaly or birth defect. 6. Important medical events that may not result in death, be life threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
The Percent of Participants Who Experience a Serious Adverse Event
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants Who Experience a Serious Adverse Event40
SecondaryThe Percent of Participants Who Experience Infusion Reactions

The number of participants with infusion reactions reported as AEs. Infusion reactions are defined as any adverse reaction within 24 hours of infusion which are Grade 2 or higher events and at least possibly related to study drug. The severity of AEs was classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.

Time frame:
Up to 24 hours post treatment infusion
Reported as:
Count of participants · Participants
The Percent of Participants Who Experience Infusion Reactions
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
The Percent of Participants Who Experience Infusion Reactions10
SecondaryThe Percent of Participants That Reach the Following Threshold Levels of IgG4-Related Disease Responder Index (IgG4-RD RI) Improvement at 24 Weeks: 50% and 75%.

The IgG4-RD RI detects change in disease activity and identifies improvements/worsening in the same or different organ systems. It encompasses more than 25 organs/sites and records the following for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. The final activity score at each visit is obtained by summing all organ/site scores (i) and by doubling items needing urgent care (iii). Higher scores represent greater (i.e. worse) disease activity. % improvement in the IgG4-RD RI = 100 x ( (Baseline IgG4-RD RI Activity Score - Week 24 IgG4-RD RI Activity Score) / Baseline IgG4-RD RI Activity Score). Participants who use glucocorticoids/immunosuppressants beyond that permitted by protocol, or who experience a disease flare before 24 weeks will be defined as achieving no disease response (0%).

Time frame:
Baseline and Week 24
Reported as:
Count of participants · Participants
The Percent of Participants That Reach the Following Threshold Levels of IgG4-Related Disease Responder Index (IgG4-RD RI) Improvement at 24 Weeks: 50% and 75%.
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
50% Improvement20
75% Improvement20
SecondaryNumber of Participants With Disease Flares

IgG4-Related Disease flare was defined as recurrence of disease activity such that additional immunosuppressive therapy beyond the trial protocol is indicated. Such additional therapy may include glucocorticoids or alternative immunosuppressive agents. At the time of a potential disease flare, investigators documented the features of the disease flare in each involved organ, including laboratory evaluations, radiology studies, and other procedures (e.g., biopsy). Disease flares were reported as adverse events.

Time frame:
Up to Week 48 post treatment initiation
Reported as:
Count of participants · Participants
Number of Participants With Disease Flares
ParticipantsCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Number of Participants With Disease Flares42
SecondaryChange From Baseline in Physician Global Assessment

The Physician Global Assessment of the participant's current disease activity was recorded on a 100 mm linear horizontal visual analog scale, where the left hand extreme of the line is considered "Very Good" (0 mm, symptom free and no IgG4-RD symptoms) and the right hand extreme is considered "Very Bad" (100 mm, maximum IgG4-RD activity). Only active disease (as opposed to damage) is considered in the scoring. Change was calculated as the value at Week 12, 24 or 48 minus the value at Baseline.

Time frame:
Baseline, Weeks 12, 24 and 48
Reported as:
Mean · millimeter
Change From Baseline in Physician Global Assessment
millimeterCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Week 12—3.0 ± 24.04
Week 24-18.5 ± 15.60—
Week 48-30.0 ± 17.32—
SecondaryChange From Baseline in Patient Global Assessment

The Patient Global Assessment of the participant's current disease activity was recorded on a 100 mm linear horizontal visual analog scale, where the left hand extreme of the line is considered "Very Good" (0 mm, symptom free and no IgG4-RD symptoms) and the right hand extreme is considered "Very Bad" (100 mm, maximum IgG4-RD activity). Change was calculated as the value at Week 12, 24 or 48 minus the value at Baseline.

Time frame:
Baseline, Weeks 12, 24 and 48
Reported as:
Mean · millimeter
Change From Baseline in Patient Global Assessment
millimeterCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Week 12—-15.0 ± 32.53
Week 2418.8 ± 40.53—
Week 4817.0 ± 34.04—
SecondaryDisease-Related Damage, as Measured by the Damage Section of the IgG4-Related Disease (IgG4-RD) Responder Index.

An assessment of damage caused by IgG4-RD in each affected organ is part of the Responder Index. The IgG4-RD RI encompasses more than 25 organs/sites and records the following set of information for each organ/site: (i) activity trend (through a 0-3 \[normal/resolved - worsening\] organ/site score); (ii) presence of symptoms due to active disease; (iii) need for urgent care; (iv) presence of damage; and (v) presence of symptoms due to damage. Activity and damage are considered separately from the standpoint of scoring, because only disease activity can be expected to respond to treatment. Damage is defined as organ dysfunction that has occurred as a result of IgG4-RD and is considered permanent. The total damage score at each visit is defined as the total number of damaged organs and can range from 0 (no damage) to more than 26 (severe damage).

Time frame:
Screening and Week 24
Reported as:
Mean · Scores on a scale
Disease-Related Damage, as Measured by the Damage Section of the IgG4-Related Disease (IgG4-RD) Responder Index.
Scores on a scaleCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Screening1.3 ± 1.210 ± 0
Week 241.5 ± 1.52—

Adverse events

Collected over Up to Week 48 post treatment initiation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone Taper0/6 (0%)4/6 (66.7%)6/6 (100%)
Cohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
COVID-19Infections and infestations2/60/2
Abdominal painGastrointestinal disorders1/60/2
AppendicitisInfections and infestations1/60/2
Hip fractureInjury, poisoning and procedural complications1/60/2
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone Taper
Immunoglobulin G4 related diseaseImmune system disorders4/62/2
COVID-19Infections and infestations2/60/2
TachycardiaCardiac disorders1/60/2
Cushing's syndromeEndocrine disorders1/60/2
Abdominal painGastrointestinal disorders1/60/2
Secondary immunodeficiencyImmune system disorders1/60/2
BronchitisInfections and infestations1/60/2
Infusion related reactionInjury, poisoning and procedural complications1/60/2
Alanine aminotransferase increasedInvestigations1/60/2
Blood albumin decreasedInvestigations1/60/2

Baseline characteristics

Enrolled

Age, Categorical
Age, Categorical(Participants)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
<=18 years000
Between 18 and 65 years224
>=65 years404
Age, Continuous
Age, Continuous(years)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
Mean63.8 ± 6.2756.0 ± 0.0061.9 ± 6.42
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
Female123
Male505
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
Hispanic or Latino000
Not Hispanic or Latino628
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White505
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
United States628
IgG4-Related Disease Responder Index (IgG4-RD RI) Total Activity Score
IgG4-Related Disease Responder Index (IgG4-RD RI) Total Activity Score(Scores on a scale)Cohort 1a: Elotuzumab, 1-Month Regimen + Prednisone TaperCohort 1b: Elotuzumab, 12-Month Regimen + Prednisone TaperTotal
Mean9.3 ± 3.017.0 ± 4.248.8 ± 3.20
08

Study locations

3 sites
  • Emory Healthcare
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic: Pulmonary and Critical Care Medicine
    Rochester, Minnesota 55905, United States
09

References and documents

Publications

  • Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, Hart PA, Inoue D, Kawano M, Khosroshahi A, Lanzillotta M, Okazaki K, Perugino CA, Sharma A, Saeki T, Schleinitz N, Takahashi N, Umehara H, Zen Y, Stone JH; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. PubMed 31796497 ↗
  • Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, Chari ST, Della-Torre E, Frulloni L, Goto H, Hart PA, Kamisawa T, Kawa S, Kawano M, Kim MH, Kodama Y, Kubota K, Lerch MM, Lohr M, Masaki Y, Matsui S, Mimori T, Nakamura S, Nakazawa T, Ohara H, Okazaki K, Ryu JH, Saeki T, Schleinitz N, Shimatsu A, Shimosegawa T, Takahashi H, Takahira M, Tanaka A, Topazian M, Umehara H, Webster GJ, Witzig TE, Yamamoto M, Zhang W, Chiba T, Stone JH; Second International Symposium on IgG4-Related Disease. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheumatol. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132. No abstract available. PubMed 25809420 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Time frame: On average, within 24 months after database lock for the trial.

Access criteria: Open access.

Data sharing details ↗ · www.immport.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2024, 26 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2021
First posted
Jun 8, 2021
StartActual
Oct 13, 2021
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 4, 2024
Results first posted
Feb 25, 2025
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04918147
Collaborators
Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2021
Start date
Oct 13, 2021
Primary completion
Jan 4, 2024
Completion
Jan 4, 2024
Results posted
Feb 25, 2025
Last update
Feb 5, 2026

Study contacts

John H. Stone, MD, MPH
study chair · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elotuzumab

Start the discussion